Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Investigational New Drugs
Published in: Investigational New Drugs 1/2009

01-02-2009 | SHORT REPORT

Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma

Authors: Thomas W. Flaig, Fernando J. Kim, Francisco G. La Rosa, Kathryn Breaker, Jonathan Schoen, Paul D. Russ

Published in: Investigational New Drugs | Issue 1/2009

Login to get access

Excerpt

A woman with renal cell carcinoma (RCC) presented with sudden right sided flank pain and anuria. Two years earlier she was diagnosed with RCC clear cell type and had a left-sided nephrectomy performed at that time. Her initial staging evaluation revealed multiple pulmonary nodules consistent with metastatic disease and she was started on sorafenib therapy. She remained on this therapy for 9 months, but was then found to have progressive disease and high-dose interleukin-2 (IL2) was initiated. The patient developed bilateral pulmonary edema during her initial course of IL2 which was believed to be secondary to IL2-induced capillary leak and required endotracheal intubation. Accordingly, IL2 was abandoned without completing a full course and treatment with sunitinib (50 mg daily for 4 weeks followed by a 2 week break) was pursued. …
Literature
1.
2.
3.
Sugrue M, Kozloff M, Hainsworth J et al (2006) Risk factors for gastrointestinal perforations in patients with metastatic colorectal cancer receiving bevacizumab plus chemotherapy. J Clin Oncol, 2006 ASCO Annual Meeting Proceedings Part I 24:3535
4.
5.
6.
7.
Demetri GD, van Oosterom AT, Garrett CR et al (2006) Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial. Lancet 368:1329–1338PubMedCrossRef
8.
Gore M, Porta C, Oudard S et al (2007) Sunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis. J Clin Oncol, 2007 ASCO Annual Meeting Proceedings Part I 25:5010
9.
10.
Saltz LB, Clarke S, Diaz-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019 DOI 10.​1200/​JCO.​2007.​14.​9930 PubMedCrossRef
11.
Garcia AA, Hirte H, Fleming F et al (2008) Phase III clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortium. J Clin Oncol 26:76–82 DOI 10.​1200/​JCO.​2007.​12.​1939 PubMedCrossRef
12.
Berger RA, Sill MW, Monk BJ et al (2007) Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a gynecologic oncology group study. J Clin Oncol 25:5165–5177 DOI 10.​1200/​JCO.​2007.​11.​5345 CrossRef
13.
14.
15.
Heng Y, Schuffler MD, Haggitt RC et al (1995) Pneumatosis intestinalis: a review. Am J Gastroenterol 90:1747–1758PubMed
16.
Metadata
Title
Colonic pneumatosis and intestinal perforations with sunitinib treatment for renal cell carcinoma
Authors
Thomas W. Flaig
Fernando J. Kim
Francisco G. La Rosa
Kathryn Breaker
Jonathan Schoen
Paul D. Russ
Publication date
01-02-2009
Publisher
Springer US
Published in
Investigational New Drugs / Issue 1/2009
Print ISSN: 0167-6997
Electronic ISSN: 1573-0646
DOI
https://doi.org/10.1007/s10637-008-9146-z

Other articles of this Issue 1/2009

Investigational New Drugs 1/2009 Go to the issue

PRECLINICAL STUDIES

Development of water soluble derivatives of cis-3, 4′, 5-trimethoxy-3′-aminostilbene for optimization and use in cancer therapy

SHORT REPORT

Inhibition of protein synthesis by imexon reduces HIF-1α expression in normoxic and hypoxic pancreatic cancer cells

PRECLINICAL STUDIES

The effect of P-gp (Mdr1a/1b), BCRP (Bcrp1) and P-gp/BCRP inhibitors on the in vivo absorption, distribution, metabolism and excretion of imatinib

PRECLINICAL STUDIES

Antitumor activity of a novel EGFR tyrosine kinase inhibitor against human lung carcinoma in vitro and in vivo

PHASE II STUDIES

Docetaxel and epirubicin salvage regimen in relapsed anthracycline-sensitive metastatic breast cancer patients after anthracycline-containing adjuvant therapy

PHASE I STUDIES

A phase I study of bortezomib, etoposide and carboplatin in patients with advanced solid tumors refractory to standard therapy
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits